Floatz logo

Gavo-Cel

Mesothelioma; Pleura

TCR2 TherapeuticsPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Mesothelioma; Pleura cohort.

Asset / SponsorPhaseRating
Regorafenib
Institut Bergonié
Phase 1/2CCC
Nivolumab
TCR2 Therapeutics
Phase 1/2CCC
tc-510
TCR2 Therapeutics
Phase 1/2CCC
Ipilimumab
TCR2 Therapeutics
Phase 1/2CCC
Cyclophosphamide
TCR2 Therapeutics
Phase 1/2CCC

View all 12 →

Same molecule, other indications

Gavo-Cel is also rated in:

peritoneal mesotheliomaDormant
CCC
Indicative ·
48 / 100
View asset →
ovarian serous adenocarcinomaDormant
CC
Indicative ·
47 / 100
View asset →
malignant mesotheliomaDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →